# Shape Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shape-therapeutics

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.shapetx.com
- Total disclosed funding: $148M
- Latest round: Series B (Jul 15, 2021)
- Investors on record: 6

## About

Based in Washington, US, and founded in 2018 by co-founders Francois Vigneault, John Suliman, and Prashant Mali, Shape Therapeutics, Inc., trading under the name ShapeTX, is a biotechnology company developing RNA technologies. Francois Vigneault is the current CEO of the company. In July 2021, Shape Therapeutics, Inc. raised USD 112 million in series B funding co-led by new investors Breton Capital Ventures and Decheng Capital, with participation from another new investor, Willett Advisors LLC.

ShapeTX is a gene therapy platform designed to facilitate the treatment of neurodegenerative disorders, oncology, metabolic, and rare genetic diseases, such as Parkinson’s disease, Alzheimer’s disease, alpha-1 antitrypsin deficiency, and Rett syndrome. The company has developed a suite of technology platforms that broadly enable RNA targeting, RNA editing, and RNA replacement for patients suffering from genetic disorders with high unmet needs. Its solutions include Payload – RNA Fix, Payload – RNA Skip, and Delivery – AAVid.

The company plans to continue building its growing portfolio of RNA technologies into broad industry verticals while accelerating the development of groundbreaking treatment approaches for patients by prioritizing key partnership opportunities.

## Funding rounds

- Series B, Jul 15, 2021, $112M — New Enterprise Associates, Decheng Capital, Breton Capital Ventures, Mission Biocapital, Willett Advisors LLC
- Series A, Nov 5, 2019, $36M — New Enterprise Associates, CureDuchenne Ventures

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B
- CureDuchenne Ventures (https://capitalatlas.ai/funds/cureduchenne-ventures) — Series A
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series B
- Breton Capital Ventures (https://capitalatlas.ai/funds/breton-capital-ventures) — Series B
- Mission Biocapital (https://capitalatlas.ai/funds/mission-biocapital) — Series B
- Willett Advisors LLC — Series B